AKRO - Expected Trial Completion for Efruxifermin Study in Compensated Cirrhosis Due to NASH/MASH
Oct 1, 2029, 4:00:00 AM UTC
Summary
Akero Therapeutics is conducting a Phase 3, randomized, double-blind, placebo-controlled trial of efruxifermin (EFX) in 1,150 subjects with compensated cirrhosis due to NASH/MASH. The study is expected to complete on October 1, 2029. Efruxifermin is an investigational FGF21 analog targeting metabolic and fibrotic pathways in NASH/MASH, a progressive liver disease with limited treatment options.
Company
AKERO THERAPEUTICS INC (AKRO)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.akerotx.comSimilar Events
Expected Completion of Efruxifermin Phase 3 Trial in NASH/MASH
Akero Therapeutics is conducting a Phase 3, randomized, double-blind, placebo-controlled trial of efruxifermin (EFX) in 1,650 subjects with non-cirrhotic NASH/MASH and fibrosis stages F2 or F3. The trial is expected to complete on November 1, 2032. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The study's outcome will inform potential regulatory submissions for EFX in NASH/MASH.
trial completionPhase 3 Efruxifermin NASH/MASH Trial Completion Expected
Akero Therapeutics is conducting a Phase 3 clinical trial of Efruxifermin (EFX) in patients with non-invasively diagnosed nonalcoholic steatohepatitis (NASH/MASH) and nonalcoholic fatty liver disease (NAFLD/MASLD). The study, enrolling 700 participants, is expected to complete on October 1, 2026. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The trial's primary objective is to assess safety and tolerability compared to placebo.
trial completionPhase 3 Clinical Trial Completion for Pegozafermin in MASH Cirrhosis
89bio, Inc. is conducting a Phase 3 clinical trial evaluating pegozafermin in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The study, enrolling 762 participants, is expected to complete on August 1, 2031. Pegozafermin is a glycopegylated analog of FGF21, under development for liver and metabolic diseases. The trial's outcome may impact future regulatory submissions and commercial prospects for pegozafermin in advanced MASH.
trial completionENLIGHTEN-Fibrosis Phase 3 Trial Completion for Pegozafermin
89bio's Phase 3 ENLIGHTEN-Fibrosis trial evaluating pegozafermin in adults with MASH (formerly NASH) and stage 2 or 3 liver fibrosis is expected to complete on February 1, 2029. The study, currently recruiting 1,050 participants, will assess the efficacy and safety of two dosing regimens. Pegozafermin is a glycopegylated analog of FGF21, developed for metabolic and liver diseases. Trial results could impact the competitive landscape for MASH therapies.
trial completion